Skip to main content
PMC home page
Archives of Disease in Childhood logoLink to Archives of Disease in Childhood
. 1990 Aug;65(8):822–825. doi: 10.1136/adc.65.8.822

5-HT3 antagonist ondansetron--an effective outpatient antiemetic in cancer treatment.

C R Pinkerton 1, D Williams 1, C Wootton 1, S T Meller 1, T J McElwain 1
PMCID: PMC1792498  PMID: 2144721

Abstract

Thirty children aged 2-16 years with malignant tumours who were receiving chemotherapy were treated with the 5-HT3 antagonist ondansetron. Each received a single intravenous dose (5 mg/m2) followed by oral doses (2-4 mg depending on surface area) every eight hours for five days. Chemotherapy regimens comprised: carboplatin alone, carboplatin plus etoposide, cisplatin plus etoposide; adriamycin (doxorubicin) plus cyclophosphamide, or ifosfamide. Twelve patients received ondansetron with their first course of chemotherapy and the other patients were poor responders to previous antiemetic treatment. Efficacy was assessed by a questionnaire documenting the incidence of vomiting and severity of nausea. In a 24 hour period after starting chemotherapy a complete or major response (less than two vomiting episodes) was achieved in 87% of children. Although ondansetron was effective for early antiemesis after cisplatin or ifosfamide, delayed vomiting, retching, or nausea reduced responses to 50% and 20%, respectively. We conclude that in children ondansetron is an effective, well tolerated, oral antiemetic enabling simple administration in the outpatient setting. In the present schedule it was of limited efficacy against cisplatin or ifosfamide induced emesis.

Full text

PDF
822

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bermudez J., Boyle E. A., Miner W. D., Sanger G. J. The anti-emetic potential of the 5-hydroxytryptamine3 receptor antagonist BRL 43694. Br J Cancer. 1988 Nov;58(5):644–650. doi: 10.1038/bjc.1988.277. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Cassidy J., Raina V., Lewis C., Adams L., Soukop M., Rapeport W. G., Zussman B. D., Rankin E. M., Kaye S. B. Pharmacokinetics and anti-emetic efficacy of BRL43694, a new selective 5HT-3 antagonist. Br J Cancer. 1988 Nov;58(5):651–653. doi: 10.1038/bjc.1988.278. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Coupe M. Adverse reaction to 5-HT3 antagonist ICS 205930. Lancet. 1987 Jun 27;1(8548):1494–1494. doi: 10.1016/s0140-6736(87)92246-x. [DOI] [PubMed] [Google Scholar]
  4. Cunningham D., Hawthorn J., Pople A., Gazet J. C., Ford H. T., Challoner T., Coombes R. C. Prevention of emesis in patients receiving cytotoxic drugs by GR38032F, a selective 5-HT3 receptor antagonist. Lancet. 1987 Jun 27;1(8548):1461–1463. doi: 10.1016/s0140-6736(87)92208-2. [DOI] [PubMed] [Google Scholar]
  5. Cunningham D., Turner A., Hawthorn J., Rosin R. D. Ondansetron with and without dexamethasone to treat chemotherapy-induced emesis. Lancet. 1989 Jun 10;1(8650):1323–1323. doi: 10.1016/s0140-6736(89)92711-6. [DOI] [PubMed] [Google Scholar]
  6. Green J. A., Watkin S. W., Hammond P., Griggs J., Challoner T. The efficacy and safety of GR38032F in the prophylaxis of ifosfamide-induced nausea and vomiting. Cancer Chemother Pharmacol. 1989;24(2):137–139. doi: 10.1007/BF00263137. [DOI] [PubMed] [Google Scholar]
  7. Kris M. G., Gralla R. J., Clark R. A., Tyson L. B. Dose-ranging evaluation of the serotonin antagonist GR-C507/75 (GR38032F) when used as an antiemetic in patients receiving anticancer chemotherapy. J Clin Oncol. 1988 Apr;6(4):659–662. doi: 10.1200/JCO.1988.6.4.659. [DOI] [PubMed] [Google Scholar]
  8. Leibundgut U., Lancranjan I. First results with ICS 205-930 (5-HT3 receptor antagonist) in prevention of chemotherapy-induced emesis. Lancet. 1987 May 23;1(8543):1198–1198. doi: 10.1016/s0140-6736(87)92159-3. [DOI] [PubMed] [Google Scholar]
  9. Marty M., Pouillart P., Scholl S., Droz J. P., Azab M., Brion N., Pujade-Lauraine E., Paule B., Paes D., Bons J. Comparison of the 5-hydroxytryptamine3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis. N Engl J Med. 1990 Mar 22;322(12):816–821. doi: 10.1056/NEJM199003223221205. [DOI] [PubMed] [Google Scholar]
  10. de Haan L. D., de Mulder P. H., Beex L. V., Debruyne F. M., Challoner T., de Pauw B. E. The efficacy of GR38032F, an antagonist of 5-hydroxytryptamine-3 (5-HT3) in the prophylaxis of cisplatin (CDDP)-induced nausea and vomiting. Eur J Cancer Clin Oncol. 1988 Aug;24(8):1383–1384. doi: 10.1016/0277-5379(88)90235-0. [DOI] [PubMed] [Google Scholar]

Articles from Archives of Disease in Childhood are provided here courtesy of BMJ Publishing Group

RESOURCES